Skip Navigation


Annals of Oncology Advance Access originally published online on February 10, 2007
Annals of Oncology 2007 18(5):874-880; doi:10.1093/annonc/mdm008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/5/874    most recent
mdm008v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mazouni, C
Right arrow Articles by Pusztai, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mazouni, C
Right arrow Articles by Pusztai, L
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

breast cancer

Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers

C Mazouni1, S-W Kau1, D Frye1, F Andre1, HM Kuerer2, TA Buchholz3, WF Symmans4, K Anderson5, KR Hess5, AM Gonzalez-Angulo1, GN Hortobagyi1, AU Buzdar1 and L Pusztai1,*

1 Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 Department of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
4 Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
5 Department of Biostatistics and Applied Mathematics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

* Correspondence to: Dr L. Pusztai, Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Unit1354, PO Box 301439, Houston TX 77230-1439, USA. Tel: +1-713-792-2817, Fax: +1-713-794-4385, E-mail: lpusztai{at}mdanderson.org

Background: We examined if inclusion of a taxane and more prolonged preoperative chemotherapy improves pathologic complete response (pCR) rate in estrogen receptor (ER)-positive breast cancer compared with three to four courses of 5-fluorouracil, doxorubicin, cyclophosphamide (FAC).

Patients and methods: Pooled analysis of results from seven consecutive neo-adjuvant chemotherapy trials including 1079 patients was carried out. These studies were conducted at MD Anderson Cancer Center from 1974 to 2001. Four hundred and twenty-six (39.5%) patients received taxane-based neo-adjuvant therapy. pCR rates and survival times were analyzed as a function of chemotherapy regimen and ER status. Multivariate logistic and Cox regression analysis were carried out to identify variables associated with pCR and survival.

Results: Patients with ER-negative cancer had higher overall pCR rate than patients with ER-positive tumors (20.1% versus 4.9%, P < 0.001). In ER-negative patients, the pCR rates were 29% and 15% with and without a taxane (P < 0.001). In ER-positive patients, the pCR rates were 8.8% and 2.0% with and without a taxane (P < 0.001). In multivariate analysis, clinical tumor size (P < 0.001), ER-negative status (P < 0.001) and inclusion of a taxane (P = 0.01) were independently associated with pCR. For patients with pCR, survival was similar regardless of ER status or the type of regimen that induced pCR.

Conclusion: pCR rates increased for patients with both ER-positive and ER-negative tumors as regimens started to include a taxane and became longer. This indicates that a subset of patients with ER-positive breast cancer benefits from more aggressive chemotherapy, similarly to patients with ER-negative tumors.

Key words: breast cancer, estrogen receptor, neo-adjuvant, pCR, taxanes

Received for publication November 7, 2006. Revision received January 8, 2007. Accepted for publication January 9, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
F. Andre, K. Broglio, H. Roche, M. Martin, J. R. Mackey, F. Penault-Llorca, G. N. Hortobagyi, and L. Pusztai
Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis
J. Clin. Oncol., June 1, 2008; 26(16): 2636 - 2643.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. von Minckwitz, S. Kummel, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S. D. Costa, C. Jackisch, et al.
Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study
J Natl Cancer Inst, April 16, 2008; 100(8): 552 - 562.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Pusztai
Current Status of Prognostic Profiling in Breast Cancer
Oncologist, April 1, 2008; 13(4): 350 - 360.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.